Objective:To investigate the therapeutic effect and safety of ertugliflozin combined with metformin in the treatment of patients with overweight/obese type 2 diabetes mellitus(T2DM).Methods:108 overweight/obese T2DM patients were included and divided into metformin group(n=54)and ertugliflozin group(n=54)according to different treatment methods.The metformin group received metformin,whereas the ertugliflozin group was given metformin+ertugliflozin.The blood glucose indexes[FBG,2 h postpran-dial blood glucose(2 hPBG),glycosylated hemoglobin(HbA1c)],insulin function indexes[fasting insulin(FINS),HOMA-β,HO-MA-IR],body mass index(BMI),waist hip ratio(WHR),lipid metabolism indexes(TC,TG,LDL,HDL)and adverse reaction were compared between the two groups at 3 months of treatment.Results;At 3 months of treatment,the FPG,2 hPBG,HbA1c,FINS,HOM A-IR,BMI,WHR,TC,TG and LDL in both groups were reduced(P＜0.05),and the levels in ertugliflozin group were lower than those in metformin group(P＜0.05).The HOMA-β and HDL were enhanced(P＜0.05),and the levels were higher in ertugliflozin group(P＜0.05).There were no statistical differences in the incidence rates of adverse reactions between groups(P＞0.05).Conclusion:Ertugliflozin combined with metformin can reduce the blood glucose,and improve the insulin function and lipid metabolism indexes of patients with overweight/obese T2DM,and will not increase the incidence rates of adverse reactions,it has a good clinical application preospect.